Pregistry, LLC (“Pregistry”), a world authority in safety studies conducted during pregnancy, has been acquired by CorEvitas LLC (“CorEvitas”), a market leader in syndicated registries. The acquisition, which makes up CorEvitas’ fifth acquisition, broadens the company’s access to real-world research by incorporating retrospective claims studies and syndicated prenatal observational studies. The agreement’s terms weren’t made public.

Pregistry, a company founded in 2014, draws on the knowledge of more than 70 pregnancy specialists to address a variety of clinical, safety, regulatory, marketing, and technological concerns. The result is information that promotes successful pregnancies and deliveries. The data from Pregistry provides information about health and safety during and after pregnancy to individuals, service providers, and industry stakeholders. It makes sure that prescribers, regulators, and pharmaceutical firms have the knowledge necessary to comprehend the possible advantages and disadvantages of drugs and vaccinations during pregnancy. Pregistry collaborates with major pharmaceutical and biotechnology firms to carry out observational research on the safety of medications and vaccines during pregnancy.

CorEvitas’s growth to satisfy international regulatory standards for the security of drugs and vaccinations during pregnancy

With this financing, CorEvitas is able to expedite the development of syndicated registries and add to its extensive background in conducting post-approval safety studies for autoimmune and inflammatory-mediated disorders. For the purpose of researching the practical efficacy and safety of cutting-edge medicines, CorEvitas has 20 years of experience in designing and monitoring specialised patient registries.

Source: Prnewswire